586 related articles for article (PubMed ID: 16010587)
21. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
[TBL] [Abstract][Full Text] [Related]
22. Epitope diversification driven by non-tumor epitope-specific Th1 and Th17 mediates potent antitumor reactivity.
Ichikawa K; Kagamu H; Koyama K; Miyabayashi T; Koshio J; Miura S; Watanabe S; Yoshizawa H; Narita I
Vaccine; 2012 Sep; 30(43):6190-7. PubMed ID: 22889826
[TBL] [Abstract][Full Text] [Related]
23. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
24. Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0.
Barnard A; Mahon BP; Watkins J; Redhead K; Mills KH
Immunology; 1996 Mar; 87(3):372-80. PubMed ID: 8778021
[TBL] [Abstract][Full Text] [Related]
25. Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.
Fonseca DP; Benaissa-Trouw B; van Engelen M; Kraaijeveld CA; Snippe H; Verheul AF
Infect Immun; 2001 Aug; 69(8):4839-45. PubMed ID: 11447158
[TBL] [Abstract][Full Text] [Related]
26. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
27. Novel genetic regulation of T helper 1 (Th1)/Th2 cytokine production and encephalitogenicity in inbred mouse strains.
Conboy IM; DeKruyff RH; Tate KM; Cao ZA; Moore TA; Umetsu DT; Jones PP
J Exp Med; 1997 Feb; 185(3):439-51. PubMed ID: 9053444
[TBL] [Abstract][Full Text] [Related]
28. Mannosylated T/Tn with Freund's adjuvant induces cellular immunity.
Son HY; Apostolopoulos V; Kim CW
Int J Immunopathol Pharmacol; 2018; 31():394632017742504. PubMed ID: 29251002
[TBL] [Abstract][Full Text] [Related]
29. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
[TBL] [Abstract][Full Text] [Related]
30. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
31. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer.
McNeel DG; Nguyen LD; Ellis WJ; Higano CS; Lange PH; Disis ML
Prostate; 2001 May; 47(3):222-9. PubMed ID: 11351352
[TBL] [Abstract][Full Text] [Related]
32. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
[TBL] [Abstract][Full Text] [Related]
33. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.
Knutson KL; Disis ML
Clin Exp Immunol; 2004 Feb; 135(2):322-9. PubMed ID: 14738463
[TBL] [Abstract][Full Text] [Related]
34. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
[TBL] [Abstract][Full Text] [Related]
35. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
36. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
37. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
[TBL] [Abstract][Full Text] [Related]
38. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
[TBL] [Abstract][Full Text] [Related]
39. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Antiviral Cytotoxic CD4 T Cell Differentiation.
Knudson CJ; Férez M; Alves-Peixoto P; Erkes DA; Melo-Silva CR; Tang L; Snyder CM; Sigal LJ
J Virol; 2021 Sep; 95(19):e0056621. PubMed ID: 34260270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
